Acetylsalicylic acid tablets with glycine improve long-term tolerability in antiplatelet drug therapy - Results of a noninterventional trial
Acetylsalicylic acid tablets with glycine improve long-term tolerability in antiplatelet drug therapy - Results of a noninterventional trial
复制标题
DOI：
10.1007/bf02849852
复制
发表时间：
2003-09-01
影响因子：
3.8
通讯作者：
Breddin, HK
中科院分区：
文献类型：
--
作者：
Kusche, W;Paxinos, R;Breddin, HK
为了确定含有甘氨酸(Gly)的乙酰水杨酸(ASA)制剂(Gly-ASA)的耐受性，研究人员选择了1135名已经接受长期抗血小板治疗的患者进行非干预性试验，Gly-ASA每天50-300 mg。在平均42.6天的治疗后，耐受性评分和5次胃肠道(GI)主诉的频率与任何先前报告的治疗结果进行比较，包括普通的ASA。经过Gly-ASA治疗后，没有胃肠道不适的患者的平均百分比增加了2倍多，从28.2%增加到60.6%。此外，报告任何“总是”出现胃肠道症状的患者的平均百分比从8.5%下降到0.5%。98%的患者对甘氨酸-阿司匹林的耐受性评定为“优”或“良”。在10名患者(0.9%)中，Gly-ASA治疗因胃肠道不耐受(n=4)和非药物相关原因(n=6)而提前终止。就长期治疗依从性而言，这种甘氨酸-阿司匹林制剂改善的耐受性表明，与不含甘氨酸的阿司匹林替代品相比，这是一个重要的优势。
To determine the tolerability of a glycine (Gly)-containing acetylsalicylic acid (ASA) preparation (Gly-ASA), investigators selected 1135 patients already receiving long-term antiplatelet therapy for a noninterventional trial of Gly-ASA 50 to 300 mg daily. After an average treatment period of 42.6 days, tolerability rating scores and the frequency of 5 gastrointestinal (GI) complaints were compared with those reported for any previous treatment, including plain ASA. After treatment with Gly-ASA, the mean percentage of patients without GI complaints increased more than 2-fold, from 28.2% to 60.6%. Furthermore, the mean percentage of patients reporting any GI symptoms as "always" present decreased from 8.5% to 0.5%. Gly-ASA tolerability was rated "excellent" or "good" by 98% of the patients. In 10 patients (0.9%), Gly-ASA treatment was terminated prematurely due to GI intolerance (n=4) and nonmedication-related causes (n=6). With respect to long-term treatment compliance, the improved tolerability profile observed with this Gly-ASA preparation indicates an important advantage over nonglycine-containing ASA alternatives.